Atai Life Sciences N.V.
ATAI
$1.47
$0.053.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.00K | 40.00K | 273.00K | -- | 18.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.00K | 40.00K | 273.00K | -- | 18.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -5.00K | 40.00K | 273.00K | -- | 18.00K |
| SG&A Expenses | 11.44M | 10.27M | 13.40M | 10.96M | 19.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.34M | 22.64M | 26.00M | 22.19M | 33.58M |
| Operating Income | -29.35M | -22.60M | -25.73M | -22.19M | -33.56M |
| Income Before Tax | -39.71M | -26.49M | -57.35M | -27.59M | -21.16M |
| Income Tax Expenses | -718.00K | -178.00K | 19.00K | -209.00K | -2.02M |
| Earnings from Continuing Operations | -38.99M | -26.31M | -57.37M | -27.38M | -19.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 33.00K | 25.00K | 57.00K | 665.00K | 850.00K |
| Net Income | -38.96M | -26.29M | -57.31M | -26.71M | -18.29M |
| EBIT | -29.35M | -22.60M | -25.73M | -22.19M | -33.56M |
| EBITDA | -29.12M | -22.52M | -25.65M | -22.10M | -33.46M |
| EPS Basic | -0.24 | -0.16 | -0.36 | -0.17 | -0.12 |
| Normalized Basic EPS | -0.12 | -0.11 | -0.22 | -0.10 | -0.14 |
| EPS Diluted | -0.24 | -0.16 | -0.36 | -0.17 | -0.12 |
| Normalized Diluted EPS | -0.12 | -0.11 | -0.22 | -0.10 | -0.14 |
| Average Basic Shares Outstanding | 160.71M | 160.62M | 160.39M | 158.89M | 158.84M |
| Average Diluted Shares Outstanding | 160.71M | 160.62M | 160.39M | 158.89M | 158.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |